Information is power.

The single most important tool that any micro cap investor or trader has in their arsenal is information. Without in-depth information about a micro company, individual investors cannot win versus the hedge funds that trade the same micro cap stocks. The hedge funds pay their own staffs of analysts to provide the fund with objective, unbiased research on micro cap companies of interest. It is only after this intensive research effort has been completed that a hedge fund may decide to invest in the micro cap stock. Individual investors who do not have access to such objective research are at a significant disadvantage. That’s because much of the information available to the individual investor about most micro cap stocks is a “puff piece” created by the investor relations firm employed by the micro cap company.

Opportunities abound for Hedge Funds.

There are literally thousands of micro cap companies, very few of which are followed by objective research providers. This offers hedge funds enormous investment opportunities not available to individual investors due to the information imbalance. This inability of individual investors to access objective, quality, timely research on micro cap companies can be the difference between epic investment success and catastrophic failure.

Zacks is bringing independent micro cap research to individual investors - through Crowdfunding.

Zacks Microcap Indie Research Newsletter is the first Crowdfunded investment newsletter that will level the playing field between individual investors and the microcap hedge funds. Zacks Indie Research consists of a series of monthly in-depth independent research reports on a group of micro cap stocks selected by Zacks. Each month, subscribers to Zacks Indie Research will receive a new issue of the newsletter that features an in-depth research report on a different micro cap stock, plus updates on the research included in prior issues.

The unique feature of Zacks Indie Research that distinguishes Zacks from all other micro cap investment newsletters is that we do not simply pick a micro cap stock and write up a short “puff piece” on the company.

Zacks Indie Research may well recommend in our write-up, DO NOT BUY and/or SELL for a micro cap company.  While the ultimate decision to Buy, Sell or Hold is your determination and Zacks Indie Research will not give individualized advice to specific subscribers, a micro cap investor will appreciate the value of our objective research versus a newsletter that is always screaming Buy, Buy, Buy.

What makes Zacks Indie Research unique?

Zacks Indie Research is not paid for by the micro cap companies covered in the newsletter.  Instead the independent research is funded by campaign backers to provide unbiased information that they can use to their benefit in their own portfolios.

Together we can shift the power of information.

The cost to create the same kinds of research reports used by hedge fund managers who trade micro caps is prohibitive for individual investors. But through the power of Crowdfunding, we’re leading the way to make unbiased, objective micro cap research both affordable and accessible.

Our funding goal of $7,000 will provide individual backers with our first newsletter which contains an in-depth, institutional-quality research report on Ekso Bionics (EKSO) for a minimum pledge of only $150. Backers will receive a number of perks based on their commitment level, including the first issue of Zacks' Indie Research newsletter which will be focused entirely on EKSO, a group call with the Zacks’ analyst and access to non-deal roadshows.

Keep in mind that the full Indie Research newsletter report on EKSO will be entirely funded by campaign backers. It is not commissioned by EKSO or by EKSO’s Investor Relations firm.

Zacks continues to lead the pack.

Just as Zacks broke new ground for small, mid and large cap investors with improved access to information on Zacks.com in the mid-90s, we’re confident Crowdfunding research will bring on a transformational change to the micro cap research coverage available to individual investors.

Why EKSO?

To select EKSO as the company for the first issue of Zacks Indie Research Newsletter, we screened the universe of more than 3,500 micro cap companies that are not followed by any research providers based on market cap, trade volume, industry trends and more. We then looked for a company with a compelling story and found EKSO, a company pioneering new frontiers as they help survivors of spinal cord injury and stroke, or with forms of lower extremity weakness, to walk again.

EKSO has also forged partnerships with world-class institutions like UC Berkley, received research grants from the Department of Defense and licensed technology to the Lockheed Martin Corporation. They are in many of the leading rehabilitation facilities throughout the U.S. and host a variety of potential applications in the medical, military, industrial and consumer markets.

Is EKSO a good investment? We cannot say Yes or No - Yet.

The EKSO story is exciting, but our experienced Zacks’ Analyst has not yet looked under the hood to see if EKSO is a real investment opportunity, and has not determined if EKSO is a good long-term micro cap investment. Is there a chance it will be the next ACADIA Pharmaceuticals? Perhaps.

We will evaluate EKSO – within four weeks after we receive funding for the first issue of Zacks Indie Research Newsletter – and our conclusions will be available only to funders for a two week period.

The evaluation of EKSO, and subsequent companies, will be conducted by an experienced Zacks’ Analyst.

The end result of the Zacks Indie Research Project.

Evaluating the viability of a company for investment purposes takes time, experience and skill. Our Zacks’ Analyst will evaluate EKSO in depth, speak withthe company’s leadership and dig in to the intricacies of the industry. The final detailed report will include whether EKSO is a Buy/Hold/Sell recommendation and the reasoning behind the recommendation, as well as a price target for potential investors to better understand the valuation of the company.

What’s in it for you?

As part of this Indie Research Crowdfunded Equity Research campaign, Zacks will produce ongoing research on underfollowed companies that we believe show a strong propensity for dramatic growth. Zacks will select the company to be researched each month for 12 months.

The first company will be EKSO followed by companies across industries such as healthcare, tech and energy. Potential future companies could include:

▪  Healthcare: NNVC, ONVO, NEPH, ADMP, MTNB, NVLX, CMVLF, ADMP

▪  Tech: SPDL, AMBT, ISIG, INPH, IZEA

▪  Energy& Other: CTEI, XBOR, HN.V,  BLSP, GLTC, YGYI

All levels of subscription will provide you with ongoing coverage updates through your subscription term.

$150 – Backers will receive the 10+ page equity research on EKSO featured in the first issue of Zacks Indie Research newsletter. Backers receive the Zacks Indie Research newsletter two weeks prior to public release each month.

$350 – Backers will receive the 10+ page equity research on EKSO featured in the first issue, plus an additional 10+ page equity research report on a company selected by Zacks each month for two subsequent months. Backers receive the Zacks Indie Research newsletter two weeks prior to public release each month.

$600 – Backers will receive the 10+ page equity research on EKSO featured in the first issue, plus an additional 10+ page equity research report on a company selected by Zacks each month for five subsequent months. Backers receive the Zacks Indie Research newsletter two weeks prior to public release each month.

$1,200 – Backers will receive the 10+ page equity research on EKSO featured in the first issue, plus an additional 10+ page equity research report on a company selected by Zacks each month for a full year. In addition, backers at this level will receive the Zacks Indie Research newsletter two weeks prior to public release each month allowing individual investors the advantage to act on the information sooner than later for a higher probability of success. After this two-week period that gives backers time to review and act upon the research, the research report will be distributed to the public through Zacks.com, Seeking Alpha and additional outlets in our network. 

$1,500 – Backers will receive all benefits of prior levels, plus access to a 60-minute group conference call consultations with our Zacks’ Analyst who evaluates each company selected by Zacks. Backers receive the Zacks Indie Research newsletter two weeks prior to public release each month.

$2,500 – Backers will receive all benefits of prior levels, plus entry to a non-deal roadshow (travel not included), and access to webinars of content provided at all 2015 non-deal road shows. Backers receive the Zacks Indie Research newsletter two weeks prior to public release each month.

Want to help, but haven’t hit on a profitable investment of your own yet?  Please consider sharing our campaign, liking our Facebook page and helping to spread the word about this pioneering investment research method.

More on Zacks.

Zacks Crowdfunded Equity Indie Research is a division of Zacks Investment Research, an independent financial research company that has been in business since 1978. At the center of everything we do is a strong commitment to sharing our independent research and its profitable discoveries with investors. This dedication has led to an independent, verified performance that has nearly tripled the S&P 500 with an independently examined and attested average gain of +26% per year.

Performance Chart Verification and Disclaimer - Here

Today, Zacks is the 2^nd largest provider of independent equity research in the U.S. Our experienced team of 80 equity analysts follow 4,400 stocks, 800 ETFs and provide quantitative forward-looking ratings for more than 5,000 Mutual Funds. Our ability to gather, analyze and distribute this information on a timely basis gives individual investors a trading advantage.

Act today.

Give yourself the informational advantage that only a professional analyst can offer. The very same that institutional investors and Hedge Funds have been leveraging for years.

Don’t forget to support our campaign and help us spread the word about the changing state of information accessibility coming to Equity Research through our breakthrough Crowdfunding campaign.

Disclaimer

Terms and Conditions of Service

Terms and Conditions of Service: You represent that you have read and agree to be bound by the terms and conditions of service ("terms") for Zacks.com. You further agree to comply with U.S. law regarding the transmission of any data obtained from the Service (as defined herein) in accordance with the terms, not to use the Service for illegal purposes, and not to interfere or disrupt networks connected to the Service. More

Zacks Investment Research, the campaign creators (employees and consultants) and the analyst(s) that will be writing and issuing the newsletter DO NOT have a position (either long or short) in EKSO Bionics.

---